I’m glad he’s CEO, his last interview was spot on. Informative but coy on future material events. Plus he was very careful to clarify “IMO” and past tense ambiguity, no definitive statements.
Also admitted they made a mistake on BLA submission when FDA called them on it. Maybe it’s because he was in the presence of another Dr and not speaking to shareholders? Either way he needs to be consistent regardless. Also was a big fan of him not being cynical toward FDA process and getting drug into that drama. He kept the high road of saving lives and managing the business development. Loved it.
Now.... how to get revenues and get out of debt... the final corner. Which indication gets them there first?
Covid still feels ambiguous and it sounds like many drugs have benefit depending on patient history. Leron is the Swiss Army knife, people just don’t realize it yet. Takes time.
Market Data 
Markets 
AI
